We’re excited to be working with UCSF to extend the reach of precision medicine beyond cancer and into pathogen detection. Each year, underdiagnosis of pneumonia, sepsis, or encephalitis/meningitis in hospital patients results in tens of thousands of avoidable deaths, millions of excess days in the hospital, and more than $10 billion in additional costs to the healthcare system. Syapse has partnered with UCSF to apply precision medicine to this critical problem. With a $1.2 million award from the California Initiative to Advance Precision Medicine (announced in August), UCSF will develop a clinical metagenomic test for pathogen detection, partnering with Syapse to integrate test results and clinical decision support into the EMR.
Syapse will ingest patients’ clinical data from UCSF’s Epic EMR and metagenomic test results obtained in a CLIA-certified laboratory. A multidisciplinary “precision medicine consult board,” the first of its kind for infectious disease, will use Syapse’s workflow capabilities to perform a collaborative case review of patient clinical and test data. Using Syapse, the consult board will capture diagnosis and treatment recommendations and deliver the consult board’s guidance to the ordering clinician through the EMR. Syapse will also facilitate test rollout to and data integration with collaborators UCLA and UC Davis, creating a growing repository of data that researchers can use to update best practices and improve recommendations over time.
To date, most of Syapse’s efforts to make precision medicine a routine part of healthcare have focused on cancer (including our collaboration with UCSF’s own Genomic Medicine Initiative). This partnership will break new ground for Syapse, taking advantage of Syapse’s ability to integrate complex clinical and molecular data as well as to streamline clinical workflows, bringing precision medicine into practice at a growing number of institutions across the country.
(Read the full press release on UCSF's website.)